85 related articles for article (PubMed ID: 12647989)
1. Interference with EGFR signaling: paradigm for improving radiation response in cancer treatment.
Raben D; Bianco C; Helfrich B; Weng E; Ciardiello F; Harari P
Expert Rev Anticancer Ther; 2002 Aug; 2(4):461-71. PubMed ID: 12647989
[TBL] [Abstract][Full Text] [Related]
2. Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer.
Mendelsohn J; Baselga J
J Clin Oncol; 2003 Jul; 21(14):2787-99. PubMed ID: 12860957
[TBL] [Abstract][Full Text] [Related]
3. Critical update and emerging trends in epidermal growth factor receptor targeting in cancer.
Baselga J; Arteaga CL
J Clin Oncol; 2005 Apr; 23(11):2445-59. PubMed ID: 15753456
[TBL] [Abstract][Full Text] [Related]
4. Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.
Huang S; Armstrong EA; Benavente S; Chinnaiyan P; Harari PM
Cancer Res; 2004 Aug; 64(15):5355-62. PubMed ID: 15289342
[TBL] [Abstract][Full Text] [Related]
5. The EGF receptor family as targets for cancer therapy.
Mendelsohn J; Baselga J
Oncogene; 2000 Dec; 19(56):6550-65. PubMed ID: 11426640
[TBL] [Abstract][Full Text] [Related]
6. Targeting epidermal growth factor receptor signaling: early results and future trends in oncology.
Lage A; Crombet T; González G
Ann Med; 2003; 35(5):327-36. PubMed ID: 12952019
[TBL] [Abstract][Full Text] [Related]
7. Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo.
Moulder SL; Yakes FM; Muthuswamy SK; Bianco R; Simpson JF; Arteaga CL
Cancer Res; 2001 Dec; 61(24):8887-95. PubMed ID: 11751413
[TBL] [Abstract][Full Text] [Related]
8. Radiation combined with EGFR signal inhibitors: head and neck cancer focus.
Harari PM; Huang S
Semin Radiat Oncol; 2006 Jan; 16(1):38-44. PubMed ID: 16378905
[TBL] [Abstract][Full Text] [Related]
9. Epidermal growth factor receptor inhibitors in clinical development.
Dancey J
Int J Radiat Oncol Biol Phys; 2004 Mar; 58(3):1003-7. PubMed ID: 14967462
[TBL] [Abstract][Full Text] [Related]
10. A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor.
Ciardiello F; Tortora G
Clin Cancer Res; 2001 Oct; 7(10):2958-70. PubMed ID: 11595683
[TBL] [Abstract][Full Text] [Related]
11. Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting.
Matar P; Rojo F; Cassia R; Moreno-Bueno G; Di Cosimo S; Tabernero J; Guzmán M; Rodriguez S; Arribas J; Palacios J; Baselga J
Clin Cancer Res; 2004 Oct; 10(19):6487-501. PubMed ID: 15475436
[TBL] [Abstract][Full Text] [Related]
12. Epidermal growth factor receptor tyrosine kinase inhibitors: evolving role in the treatment of solid tumors.
Krozely P
Clin J Oncol Nurs; 2004 Apr; 8(2):163-8. PubMed ID: 15108418
[TBL] [Abstract][Full Text] [Related]
13. Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs): simple drugs with a complex mechanism of action?
Normanno N; Maiello MR; De Luca A
J Cell Physiol; 2003 Jan; 194(1):13-9. PubMed ID: 12447985
[TBL] [Abstract][Full Text] [Related]
14. Epidermal growth factor receptor and response of head-and-neck carcinoma to therapy.
Ang KK; Andratschke NH; Milas L
Int J Radiat Oncol Biol Phys; 2004 Mar; 58(3):959-65. PubMed ID: 14967456
[TBL] [Abstract][Full Text] [Related]
15. Clinical implications of EGFR expression in the development and progression of solid tumors: focus on non-small cell lung cancer.
Ettinger DS
Oncologist; 2006 Apr; 11(4):358-73. PubMed ID: 16614231
[TBL] [Abstract][Full Text] [Related]
16. Epidermal growth factor receptor targeting in cancer.
Mendelsohn J; Baselga J
Semin Oncol; 2006 Aug; 33(4):369-85. PubMed ID: 16890793
[TBL] [Abstract][Full Text] [Related]
17. Targeted therapies for non-small-cell lung cancer: biology, rationale, and preclinical results from a radiation oncology perspective.
Raben D; Helfrich B; Bunn PA
Int J Radiat Oncol Biol Phys; 2004; 59(2 Suppl):27-38. PubMed ID: 15142632
[TBL] [Abstract][Full Text] [Related]
18. Epidermal growth factor receptor: a promising target in solid tumours.
Laskin JJ; Sandler AB
Cancer Treat Rev; 2004 Feb; 30(1):1-17. PubMed ID: 14766123
[TBL] [Abstract][Full Text] [Related]
19. Dual inhibition: combining epidermal growth factor-targeted therapies in non-small-cell lung cancer.
Ho C; Davies A; Mack P; Gandara D
Clin Lung Cancer; 2007 Jul; 8(7):420-4. PubMed ID: 17681094
[TBL] [Abstract][Full Text] [Related]
20. EGFR inhibition in NSCLC: the emerging role of cetuximab.
Herbst RS
J Natl Compr Canc Netw; 2004 Sep; 2 Suppl 2():S41-51. PubMed ID: 19780245
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]